Beam Therapeutics CEO Evans sells 50,000 shares

Q: How many BEAM shares did CEO John M. Evans sell, and at what prices?

He sold 25,000 shares on October 15, 2026, at a weighted-average price of $23.566, with reported sales ranging from $23.23 to $23.84. On October 16, 2026, he sold 25,000 shares at a weighted-average price of $23.9838, with reported sales ranging from $23.66 to $24.56.

The trading plan was adopted June 16, 2026, before the reported exercise-and-sale transactions.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Beam Therapeutics Inc. (BEAM) reports that CEO and director John M. Evans exercised options for 25,000 shares at $1.03 per share and sold 25,000 shares at a weighted-average $23.566 per share on October 15, 2026. On October 16, he exercised another 25,000 options at $1.03 per share and sold 25,000 shares at a weighted-average $23.9838 per share. Both exercise-and-sale sequences were pursuant to a Rule 10b5-1 trading plan. An indirect holding entry lists 103,000 shares held by the John M. Evans, III 2018 Irrevocable Trust on October 15, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 50,000 shares ($1.14M approx. pre-tax spread)

Exercise and Sale 7 txns

Insider Evans John M.

Role CEO

Sold 50,000 shs ($1.19M)

Approx. gross sale proceeds $1.19M

Approx. exercise cost $52K

Approx. pre-tax spread $1.14M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) ^{F1, F4}	25,000	$0.00	$0.00
Exercise	Common Stock ^F1	25,000	$1.03	$26K
Sale	Common Stock ^{F1, F3}	25,000	$23.9838	$600K
Exercise	Stock Option (Right to Buy) ^{F1, F4}	25,000	$0.00	$0.00
Exercise	Common Stock ^F1	25,000	$1.03	$26K
Sale	Common Stock ^{F1, F2}	25,000	$23.566	$589K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 155,804 contracts (Direct); Common Stock — 1,047,205 shares (Direct); Common Stock — 103,000 shares (Indirect, By John M. Evans, III 2018 Irrevocable Trust)

Footnotes (4)

F1. The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2026.
F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.23 to $23.84, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.66 to $24.56, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4. On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter.

Key Figures

Options exercised: 25,000 shares Option exercise price: $1.03 per share Weighted-average sale price: $23.566 per share +2 more

5 metrics

Options exercised 25,000 shares October 15, 2026

Option exercise price $1.03 per share Reported exercises on October 15 and October 16, 2026

Weighted-average sale price $23.566 per share October 15, 2026; 25,000 shares sold

Weighted-average sale price $23.9838 per share October 16, 2026; 25,000 shares sold

Indirect trust holding 103,000 shares John M. Evans, III 2018 Irrevocable Trust; October 15, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy)

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BEAM shares did CEO John M. Evans sell, and at what prices?

He sold 25,000 shares on October 15, 2026, at a weighted-average price of $23.566, with reported sales ranging from $23.23 to $23.84. On October 16, 2026, he sold 25,000 shares at a weighted-average price of $23.9838, with reported sales ranging from $23.66 to $24.56.

Was John M. Evans’s BEAM stock sale made under a Rule 10b5-1 plan?

Yes. The reported option exercises and stock sales were made pursuant to a Rule 10b5-1 trading plan adopted June 16, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/16/2026 - 08:09 PM EDT Accepted by SEC EDGAR 10/16/2026 - 08:09 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Evans John M.

(Last)

(First)

(Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02142

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/15/2026		M⁽¹⁾		25,000	A	$1.03	1,072,205	D
Common Stock	10/15/2026		S⁽¹⁾		25,000	D	$23.566⁽²⁾	1,047,205	D
Common Stock	10/16/2026		M⁽¹⁾		25,000	A	$1.03	1,072,205	D
Common Stock	10/16/2026		S⁽¹⁾		25,000	D	$23.9838⁽³⁾	1,047,205	D
Common Stock								103,000	I	By John M. Evans, III 2018 Irrevocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.03	10/15/2026		M⁽¹⁾			25,000	⁽⁴⁾	07/13/2028	Common Stock	25,000	$0	180,804	D
Stock Option (Right to Buy)	$1.03	10/16/2026		M⁽¹⁾			25,000	⁽⁴⁾	07/13/2028	Common Stock	25,000	$0	155,804	D

Explanation of Responses:

1. The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.23 to $23.84, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.66 to $24.56, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter.

	By: /s/ Christine Bellon, Attorney-in-fact	10/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR